Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 100+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Atopic Dermatitis Overview
Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means skin’ and ‘itis’ means ‘inflammation.
“Atopic Dermatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Atopic Dermatitis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years. Atopic Dermatitis Key players such as – Pfizer, Kymera Therapeutics, Benevolent AI, AstraZeneca, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, are developing therapies for the Atopic Dermatitis treatment
- Atopic Dermatitis Emerging therapies such as – PF 07242813, KT-474, BEN2293, MEDI3506, SB011, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.
- In November 2022, Alphyn Biologics announced that it had completed the first cohort of its Phase IIa clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks
- In September 2022, selectION announced that it has begun dosing patients in a Phase Ib trial to evaluate safety and efficacy, including duration of clinical benefit, of si-544 in patients with mild to severe atopic dermatitis.
- In July 2022, Connect Biopharma Holdings announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients. As a result, Connect Biopharma plans to report this trial’s top-line results by year-end, earlier than originally planned.
- In May 2022, Brickell Biotech announced that the first subjects were dosed in the single ascending dose of Phase I clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis. BBI-02 is a potential first-in-class, highly selective, orally bioavailable small molecule DYRK1A inhibitor that aims to restore immune balance through modulating adaptive and innate immune responses in patients with autoimmune and inflammatory diseases
- In January 2021, Arcutis Biotherapeutics initiated a Phase III trial titled “A Phase III, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis.”
Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Atopic Dermatitis Pipeline Therapeutics Assessment
- Atopic Dermatitis Assessment by Product Type
- Atopic Dermatitis By Stage and Product Type
- Atopic Dermatitis Assessment by Route of Administration
- Atopic Dermatitis By Stage and Route of Administration
- Atopic Dermatitis Assessment by Molecule Type
- Atopic Dermatitis by Stage and Molecule Type
DelveInsight’s Atopic Dermatitis Report covers around 100+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Atopic Dermatitis Therapeutics Market include:
Key companies developing therapies for Atopic Dermatitis are – Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Sciences, and others.
Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:
- PF 07242813: Pfizer
- KT-474: Kymera Therapeutics
- BEN2293: Benevolent AI
- MEDI3506: AstraZeneca
- SB011: Sterna Biologicals
- Tradipitant: Vanda Pharmaceuticals
- Roflumilast: Arcutis Biotherapeutics
Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment
Atopic Dermatitis Pipeline Analysis:
The Atopic Dermatitis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
- Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies
Atopic Dermatitis Pipeline Market Drivers
- Rising prevalence of Atopic Dermatitis
- Escalating expenditure on health care
- Potential Emerging Therapies
Atopic Dermatitis Pipeline Market Barriers
- Over-the-counter medications
- Outdated treatment recommendations
- Poor prognosis and treatment adherence
Scope of Atopic Dermatitis Pipeline Drug Insight
- Coverage: Global
- Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, Benevolent AI, AstraZeneca, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others
- Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, SB011, Tradipitant, Roflumilast, and others
- Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
- Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers
Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials
Table of Contents
| 1 | Atopic Dermatitis Report Introduction |
| 2 | Atopic Dermatitis Executive Summary |
| 3 | Atopic Dermatitis Overview |
| 4 | Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment |
| 5 | Atopic Dermatitis Pipeline Therapeutics |
| 6 | Atopic Dermatitis Late Stage Products (Phase II/III) |
| 7 | Atopic Dermatitis Mid Stage Products (Phase II) |
| 8 | Atopic Dermatitis Early Stage Products (Phase I) |
| 9 | Atopic Dermatitis Preclinical Stage Products |
| 10 | Atopic Dermatitis Therapeutics Assessment |
| 11 | Atopic Dermatitis Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Atopic Dermatitis Key Companies |
| 14 | Atopic Dermatitis Key Products |
| 15 | Atopic Dermatitis Unmet Needs |
| 16 | Atopic Dermatitis Market Drivers and Barriers |
| 17 | Atopic Dermatitis Future Perspectives and Conclusion |
| 18 | Atopic Dermatitis Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies
Related Reports:
Atopic Dermatitis Market
DelveInsight’s ‘Atopic Dermatitis-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Atopic Dermatitis Epidemiology
DelveInsight’s ‘Atopic Dermatitis Epidemiology Forecast to 2032‘ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight –
DelveInsight’s “Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market
DelveInsight’s “22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market
DelveInsight’s “X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187